MLKL

Across TCGA pan-cancer cohorts, MLKL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MLKL data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MLKL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MLKL expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where MLKL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.797	1.000	<.001	38	view →
GBM	DFS	Tertile	All	0.640	0.847	.002	15	view →
LUAD	DFS	Tertile	All	0.473	0.768	.015	11	view →
HNSC	DFS	Median	All	0.909	0.994	.005	8	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MLKL–CCRCC (OS)

Open the CCRCC breakdown →